Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin. As of later this week, retail orders also can be placed on the Dermacyte secure website at www.BuyDermacyte.com.

"Inventory of Dermacyte™ sold out quickly last fall when it was originally introduced in a market test designed to gauge customer interest and response," said Chris Stern, company chairman and CEO. "The feedback we received from customers was quite positive. We've improved the Dermacyte concentrate to be smoother and more effective. Therefore, we believe that our new cosmetic line has the potential to be a significant financial contributor to our company."

Dermacyte™ Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development. It uses the company's patented Oxycyte technology, an oxygen carrier scientifically designed to enhance oxygen delivery to tissues such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.


Oxygen Biotherapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Novel microfluidic approach to fight cancer could greatly benefit patients